null.null
Hospitals & Physicians Clinics · 51-200 Employees
View Company Info for Free
Overview
Website
www.null.nullRevenue
$5.6 MillionIndustry
About null.null
null.null Org Chart
Assistant Investigator
Is null.null your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when null.null launches new products
Funding: Get notified immidiatlly once null.null has new funding data
Click to see if null.null had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at null.null
Earning: See what the market has to say on null.null recently announced quarterly report
Check out if null.null is spiking on competitors!
Check if null.null has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
null.null, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined null.null as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
null.null is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
null.null is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about null.null.
null.null News & Media
Velocity Clinical Research's multi-site acquisitions signal new frontier for clinical site management industry
DURHAM, N.C., Sept. 22, 2021 /PRNewswire/ -- Velocity Clinical Research ("Velocity") today announces it has acquired two multi-site companies, VitaLink Research ("VitaLink") and the National Research Institute ("NRI"), for an undisclosed amount. The double acquisition adds 11 sites to...El director médico de National Research Institute, el Dr. Mark Leibowitz, comparte su experiencia como investigador principal de los ensayos para la vacuna contra el COVID-19
LOS ANGELES--(BUSINESS WIRE)--National Research Institute (NRI) ha participado en la inscripción de múltiples ensayos de vacunas contra el COVID-19, dos de los cuales han sido dirigidos por el director médico del NRI, el Dr. Mark Leibowitz, como investigador principal. El Dr. Leibowitz tiene más de 25 años de experiencia en investigación y ha participado en aproximadamente 500 estudios de la fase I-IV en una variedad de indicaciones. Como investigador principal de los estudios recientes sobreNational Research Institute’s Chief Medical Officer, Dr. Mark Leibowitz, Shares His Experience as Principal Investigator for COVID-19 Vaccine Trials
LOS ANGELES--(BUSINESS WIRE)-- #clinicaltrials--National Research Institute (NRI) has participated in the enrollment of multiple COVID-19 vaccine trials, two of which have been led by NRI’s Chief Medical Officer, Mark Leibowitz, M.D. as Principal Investigator. Dr. Leibowitz has over 25 years of research experience and has participated in an estimated 500 studies from Phase I-IV across a variety of indications. As Principal Investigator for recent COVID-19 vaccine studies, Dr. Leibowitz answers fType 2 Diabetes and Liver Disease: Twin Epidemics Call for Early Detection, Monitoring and Lifestyle Changes -- Echosens Advises Americans “Know Your Risk”
WALTHAM, Mass.--(BUSINESS WIRE)--Type 2 Diabetes and Liver Disease: Twin Epidemics Call for Early Detection, Monitoring and Lifestyle Changes
Top Hospitals & Physicians Clinics Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding null.null
National Research Institute's mission is to provide access to innovative therapies and to bring hope to the company's community through clinical research. The company's multi-disciplinary and multi-cultural organization ensures the utmost commitment to patient care, safety, and well-being. Located in Los Angeles, Huntington Park, Panorama City, and... Read More